{
    "NLTA.V": {
        "short_name": "ENLIGHTA INC",
        "long_name": "Enlighta Inc.",
        "summary": "Enlighta Inc. operates as a healthcare and medical digital, green, and clean technology company. It offers virtual medical care solutions, including disease prevention, detection, interventional therapy, and rehabilitation. The company has joint venture, intellectual property, and licensing agreements with companies, such as the Fischer Institute of Physical Therapy and Performance. It also has a patent pending portfolio of 10 OTC nutraceutical formulations. The company was formerly known as HooXi Network Inc. and changed its name to Enlighta Inc. in July 2019. Enlighta Inc. was incorporated in 2010 and is based in Road Town, the British Virgin Islands.",
        "currency": "CAD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "VAN",
        "market": "ca_market",
        "country": "British Virgin Islands",
        "state": null,
        "city": "Road Town",
        "zipcode": null,
        "website": "http://www.enlightahealth.com",
        "market_cap": "Small Cap"
    },
    "PRTG": {
        "short_name": "Portage Biotech Inc.",
        "long_name": "Portage Biotech Inc.",
        "summary": "Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "British Virgin Islands",
        "state": null,
        "city": "Tortola",
        "zipcode": "VG1110",
        "website": "http://www.portagebiotech.com",
        "market_cap": "Small Cap"
    }
}